PapersFlow Research Brief
Myeloproliferative Neoplasms: Diagnosis and Treatment
Research Guide
What is Myeloproliferative Neoplasms: Diagnosis and Treatment?
Myeloproliferative neoplasms diagnosis and treatment refers to the clinical processes for identifying and managing myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis through molecular biomarkers like JAK2 and CALR mutations, WHO classification systems, prognostic scoring, ruxolitinib therapy, and stem cell transplantation.
The field encompasses 48,661 papers on molecular pathogenesis, diagnosis, treatment, and prognosis of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and myelofibrosis. Key topics include JAK2 and CALR mutations, prognostic scoring systems, ruxolitinib therapy, hematologic response, leukemic transformation, and stem cell transplantation. WHO classifications have evolved through revisions in 2008, 2016, and 2022 to incorporate advances in biomarkers for myeloid neoplasms.
Topic Hierarchy
Research Sub-Topics
JAK2 V617F Mutation in Myeloproliferative Neoplasms
Researchers characterize the functional consequences, allele burden, and diagnostic utility of JAK2 V617F in polycythemia vera and essential thrombocythemia.
CALR Mutations in Essential Thrombocythemia
This area explores type 1/type 2 CALR frameshift mutations, megakaryocyte effects, and clinical correlations in JAK2-negative MPNs.
Ruxolitinib Therapy in Myelofibrosis
Studies evaluate spleen response, symptom control, survival benefits, and resistance mechanisms of JAK1/2 inhibition in primary myelofibrosis.
Dynamic International Prognostic Scoring System for Myelofibrosis
Researchers refine DIPSS-plus models incorporating cytogenetics, transfusion dependence, and anemia for risk-adapted treatment decisions.
Allogeneic Stem Cell Transplantation in Myeloproliferative Neoplasms
This sub-topic assesses donor selection, conditioning regimens, graft-versus-leukemia effects, and outcomes in transforming MPNs.
Why It Matters
Diagnosis relies on WHO classifications that integrate genetic mutations such as JAK2, enabling precise identification of polycythemia vera as shown in James et al. (2005) where a unique clonal JAK2 mutation causes constitutive signaling, and Královics et al. (2005) reporting a gain-of-function JAK2 mutation in a high proportion of myeloproliferative disorder patients. Treatment advances include ruxolitinib for myelofibrosis, with prognostic systems assessing hematologic response and leukemic transformation risk. For example, Arber et al. (2016) in 'The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia' updated criteria based on biomarkers, improving outcomes in stem cell transplantation candidates.
Reading Guide
Where to Start
'The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia' by Arber et al. (2016), as it provides the foundational updated diagnostic criteria incorporating biomarkers essential for understanding myeloproliferative neoplasms classification.
Key Papers Explained
Vardiman et al. (2009) in 'The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes' established baseline changes, which Arber et al. (2016) in 'The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia' built upon with new biomarkers. James et al. (2005), Královics et al. (2005), and Baxter et al. (2005) concurrently identified JAK2 mutations, linking molecular pathogenesis to these classifications. Khoury et al. (2022) in 'The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms' extends this progression.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent WHO 5th edition updates by Khoury et al. (2022) refine myeloid neoplasm classifications amid absent new preprints or news, emphasizing integration of JAK2/CALR mutations with prognostic scores for ruxolitinib and transplantation decisions.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The 2016 revision to the World Health Organization classificat... | 2016 | Blood | 10.0K | ✓ |
| 2 | World Health Organization Classification of Tumours: Pathology... | 2002 | Annals of Oncology | 4.6K | ✓ |
| 3 | International Scoring System for Evaluating Prognosis in Myelo... | 1997 | Blood | 4.4K | ✓ |
| 4 | The 2008 revision of the World Health Organization (WHO) class... | 2009 | Blood | 4.4K | ✓ |
| 5 | Genomic Classification and Prognosis in Acute Myeloid Leukemia | 2016 | New England Journal of... | 4.2K | ✓ |
| 6 | Proposals for the classification of the myelodysplastic syndromes | 1982 | British Journal of Hae... | 3.7K | ✕ |
| 7 | The 5th edition of the World Health Organization Classificatio... | 2022 | Leukemia | 3.5K | ✓ |
| 8 | A unique clonal JAK2 mutation leading to constitutive signalli... | 2005 | Nature | 3.5K | ✕ |
| 9 | A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferati... | 2005 | New England Journal of... | 3.4K | ✓ |
| 10 | Acquired mutation of the tyrosine kinase JAK2 in human myelopr... | 2005 | The Lancet | 3.4K | ✕ |
Frequently Asked Questions
What is the role of JAK2 mutations in myeloproliferative neoplasms diagnosis?
JAK2 mutations, such as the gain-of-function variant, occur in a high proportion of patients with polycythaemia vera and other myeloproliferative disorders. Královics et al. (2005) in 'A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders' identified this dominant mutation leading to constitutive signaling. Detection supports WHO classification criteria per Arber et al. (2016).
How has the WHO classification evolved for myeloid neoplasms?
The WHO classification was revised in 2008 by Vardiman et al., incorporating rationale for changes in myeloid neoplasms and acute leukemia diagnosis. Arber et al. (2016) provided the 2016 update with new biomarkers for unique myeloid neoplasms. Khoury et al. (2022) detailed the 5th edition for haematolymphoid tumours including myeloid neoplasms.
What treatments are used for myelofibrosis in myeloproliferative neoplasms?
Ruxolitinib therapy targets JAK2-driven signaling in myelofibrosis, improving hematologic response. Stem cell transplantation offers curative potential for high-risk cases with leukemic transformation risk. Prognostic scoring systems guide therapy selection as in related MDS analyses by Greenberg et al. (1997).
Which mutations are key in polycythemia vera?
A unique clonal JAK2 mutation leads to constitutive signaling causing polycythaemia vera, as reported by James et al. (2005). Acquired JAK2 tyrosine kinase mutations are prevalent in human myeloproliferative disorders per Baxter et al. (2005). These inform diagnosis under WHO criteria.
What prognostic tools apply to myeloproliferative neoplasms?
Prognostic scoring systems evaluate outcomes in related myeloid disorders like myelodysplastic syndromes, combining cytogenetics and morphology as in Greenberg et al. (1997). WHO revisions by Arber et al. (2016) and Vardiman et al. (2009) integrate such factors for myeloproliferative neoplasms. These predict leukemic transformation and treatment response.
Open Research Questions
- ? How do CALR mutations interact with JAK2 in driving myelofibrosis progression beyond initial clonal expansion?
- ? What refinements to prognostic scoring systems best predict leukemic transformation risk in ruxolitinib-treated patients?
- ? Which stem cell transplantation protocols optimize outcomes for high-risk polycythemia vera with molecular progression?
- ? How do evolving WHO criteria impact diagnostic accuracy for essential thrombocythemia variants?
- ? What are the long-term hematologic responses to targeted therapies post-JAK2 mutation identification?
Recent Trends
The field includes 48,661 works with a focus on WHO classifications evolving from 2008 (Vardiman et al.), 2016 (Arber et al.), to 2022 (Khoury et al.), alongside foundational JAK2 discoveries in 2005 by James et al., Královics et al., and Baxter et al.
No growth rate data or recent preprints/news available, maintaining emphasis on established biomarkers and ruxolitinib therapy.
Research Myeloproliferative Neoplasms: Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Myeloproliferative Neoplasms: Diagnosis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers